Kiyoharu Fukushima
Overview
Explore the profile of Kiyoharu Fukushima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fukushima K, Matsumoto Y, Matsuki T, Saito H, Motooka D, Komukai S, et al.
J Clin Microbiol
. 2023 Mar;
61(4):e0162622.
PMID: 36946719
Because nontuberculous mycobacterial pulmonary disease is a considerable health burden, a simple and clinically applicable analytical protocol enabling the identification of subspecies and drug-resistant disease is required to determine the...
12.
Niitsu T, Fukushima K, Komukai S, Takata S, Abe Y, Nii T, et al.
RMD Open
. 2023 Jan;
9(1).
PMID: 36690385
Objective: No studies have demonstrated the real-world efficacy of antifibrotics for progressive fibrosing interstitial lung disease (PF-ILD). Therefore, we evaluated the efficacy of antifibrotics in patients with PF-ILD. Methods: We...
13.
Iwahori K, Uenami T, Yano Y, Ueda T, Tone M, Naito Y, et al.
Sci Rep
. 2022 Oct;
12(1):17461.
PMID: 36261600
Anti-programmed cell death-1 (PD-1) therapy exerts beneficial effects in a limited population of cancer patients. Therefore, more accurate diagnostics to predict the efficacy of anti-PD-1 therapy are desired. The present...
14.
Matsumoto K, Shiroyama T, Kuge T, Miyake K, Yamamoto Y, Yoneda M, et al.
Transl Lung Cancer Res
. 2022 Oct;
11(9):1835-1846.
PMID: 36248332
Background: There is no clear consensus regarding the safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC) and pre-existing interstitial lung disease...
15.
Yamamoto Y, Hirata H, Shiroyama T, Kuge T, Matsumoto K, Yoneda M, et al.
Int J Chron Obstruct Pulmon Dis
. 2022 Jul;
17:1495-1506.
PMID: 35801120
Purpose: Pulmonary fibrosis and emphysema result in relatively maintained ventilation and reduced diffusing capacity. This pulmonary functional impairment complicates the evaluation of pulmonary function in patients with combined pulmonary fibrosis...
16.
Maeda Y, Motooka D, Kawasaki T, Oki H, Noda Y, Adachi Y, et al.
BMC Infect Dis
. 2022 Jun;
22(1):572.
PMID: 35751044
Background: The impact of SARS-CoV-2 infection on the gut fungal (mycobiota) and bacterial (microbiota) communities has been elucidated individually. This study analyzed both gut mycobiota and microbiota and their correlation...
17.
Kuge T, Fukushima K, Matsumoto Y, Saito H, Abe Y, Akiba E, et al.
Emerg Infect Dis
. 2022 Jun;
28(7):1437-1441.
PMID: 35731181
Unidentified Mycobacterium species are sometimes detected in respiratory specimens. We identified a novel Tsukamurella species (Tsukamurella sp. TY48, RIMD 2001001, CIP 111916), Tsukamurella toyonakaense, from a patient given a misdiagnosis...
18.
Abe Y, Fukushima K, Matsumoto Y, Niitsu T, Nabeshima H, Nagahama Y, et al.
Int J Syst Evol Microbiol
. 2022 May;
72(5).
PMID: 35604945
A slowly growing mycobacteria, identified as strain TY59, was isolated from sputum of an elderly man with pneumonia. Sequencing of the 16S rRNA gene indicated that this strain was similar...
19.
Nii T, Fukushima K, Kida H
Cell Mol Immunol
. 2022 Apr;
19(8):869-871.
PMID: 35459852
No abstract available.
20.
Futami Y, Takeda Y, Koba T, Narumi R, Nojima Y, Ito M, et al.
Int Immunol
. 2022 Mar;
34(6):327-340.
PMID: 35294531
Sarcoidosis is a complex, polygenic, inflammatory granulomatous multi-organ disease of unknown cause. The granulomatous inflammation in sarcoidosis is driven by the interplay between T cells and macrophages. Extracellular vesicles (EVs)...